Cusi K - Search Results

1

Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.

Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R. Berria R, et al. Among authors: cusi k. Clin Pharmacol Ther. 2006 Aug;80(2):105-14. doi: 10.1016/j.clpt.2006.03.014. Epub 2006 Jun 30. Clin Pharmacol Ther. 2006. PMID: 16890572

2

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

Cusi K, Consoli A, DeFronzo RA. Cusi K, et al. J Clin Endocrinol Metab. 1996 Nov;81(11):4059-67. doi: 10.1210/jcem.81.11.8923861. J Clin Endocrinol Metab. 1996. PMID: 8923861 Clinical Trial.

3

Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.

Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Cusi K, et al. J Clin Invest. 2000 Feb;105(3):311-20. doi: 10.1172/JCI7535. J Clin Invest. 2000. PMID: 10675357 Free PMC article.

4

Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.

Cusi K, DeFronzo R. Cusi K, et al. J Clin Endocrinol Metab. 2000 Sep;85(9):3077-84. doi: 10.1210/jcem.85.9.6827. J Clin Endocrinol Metab. 2000. PMID: 10999789 Clinical Trial.

5

Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes.

Cusi K, Cukier S, DeFronzo RA, Torres M, Puchulu FM, Redondo JC. Cusi K, et al. J Clin Endocrinol Metab. 2001 Mar;86(3):1410-7. doi: 10.1210/jcem.86.3.7337. J Clin Endocrinol Metab. 2001. PMID: 11238540

6

Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis.

Iozzo P, Pratipanawatr T, Pijl H, Vogt C, Kumar V, Pipek R, Matsuda M, Mandarino LJ, Cusi KJ, DeFronzo RA. Iozzo P, et al. Among authors: cusi kj. Am J Physiol Endocrinol Metab. 2001 May;280(5):E712-9. doi: 10.1152/ajpendo.2001.280.5.E712. Am J Physiol Endocrinol Metab. 2001. PMID: 11287353 Free article.

7

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Among authors: cusi k. Diabetes Care. 2001 Apr;24(4):710-9. doi: 10.2337/diacare.24.4.710. Diabetes Care. 2001. PMID: 11315836 Clinical Trial.

8

Exercise increases hexokinase II mRNA, but not activity in obesity and type 2 diabetes.

Cusi KJ, Pratipanawatr T, Koval J, Printz R, Ardehali H, Granner DK, Defronzo RA, Mandarino LJ. Cusi KJ, et al. Metabolism. 2001 May;50(5):602-6. doi: 10.1053/meta.2001.22568. Metabolism. 2001. PMID: 11319725

9

Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation.

Pratipanawatr W, Pratipanawatr T, Cusi K, Berria R, Adams JM, Jenkinson CP, Maezono K, DeFronzo RA, Mandarino LJ. Pratipanawatr W, et al. Among authors: cusi k. Diabetes. 2001 Nov;50(11):2572-8. doi: 10.2337/diabetes.50.11.2572. Diabetes. 2001. PMID: 11679436

10

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.

Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Among authors: cusi k. Diabetologia. 2001 Dec;44(12):2210-9. doi: 10.1007/s001250100031. Diabetologia. 2001. PMID: 11793023 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

248 results

Search Page